NEW DATA SUGGESTS IMPROVED TUMOR RESPONSE FOR THE COMBINATION OF AZIXA® AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER

NEW DATA SUGGESTS IMPROVED TUMOR RESPONSE FOR THE COMBINATION OF AZIXA AND
IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER 

Immune Pharmaceuticals Files New Provisional Patent Application

Immune Pharmaceuticals Inc. ("Immune" or the "Company") (NASDAQ:IMNP), a
clinical-stage biopharmaceutical company announced today that recent
preclinical experiments conducted by Dr. Boris Shor, Immunes executive director
of R&D, in collaboration with an independent U.S. based Clinical Research
Organization in a murine colon cancer model, demonstrated that the combination
of Azixa(r) and immune checkpoint inhibitors such as anti-CTLA-4 antibody
resulted in enhanced activity compared to the activity elicited by the single
agents alone, independent of the dose of Azixa(r). 

As a result, Immune has filed a provisional patent application with the United
States Patent and Trademark Office ("USPTO") relating to the combination of
Azixa(r) (veribulin), a microtubule binding vascular disrupting agent ("VDA"),
in combination with the immune checkpoint inhibitors such as an anti-CTLA-4
antibody and anti-PD1 monoclonal antibodies in the treatment of cancer. 

Azixa(r) has been noteworthy among VDAs due to it not being a substrate for
efflux pumps and achieving high CNS concentrations. One hundred and sixty-nine
patients have been treated to date with Azixa(r) in multiple phase I and phase
II clinical trials. Following this initial demonstration that the drug
functions synergistically with immune checkpoint inhibitors to enhance
suppression of growth of cancer in animal models, additional pre-clinical and
clinical studies are planned to elucidate the mechanisms underlying these
synergistic effects and the potential patient benefits. 

"Combination treatments have the potential to augment the response to immune
checkpoint inhibitors" stated Dr. Daniel Teper, CEO of Immune Pharmaceuticals,
Inc. "Azixa(r) had previously demonstrated pre-clinical and clinical activity
in multiple tumor types. The recent data opens up new potential strategic
options for the future clinical development of Azixa(r). Additionally, the new
patent, if granted, adds substantially to the patent estate surrounding
Azixa(r)." 

New York, June 28, 2016

For further information:
Danielle Shapira, Manager, Strategic Planning, IMMUNE Pharmaceuticals, Inc.,
646.440.9327, danielle.shapira@immunepharma.com
mailto:danielle.shapira@immunepharma.com 

The following documents can be retrieved from beQuoted
Immune Pharmaceuticals Pressrelease 2016-06-28.pdf -
http://www.bequoted.com/beQPress/download.asp?Id=18416 

About Azixa(r):
Azixa(r) (veribulin) is a novel microtubule destabilizer that both functions as
a potent cytotoxin and acts as a vascular disrupting agent (VDA). It is capable
of evading multidrug resistance pumps and, thus, achieves high CNS
concentrations.  It is efficacious in multiple xenograft models without CNS
toxicity. 169 patients have been treated to date with Azixa(r) in multiple
phase I and phase II clinical trials. Azixa(r) has obtained Orphan Drug
Designation in the United States for Glioblastoma (GBM). 

About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ:IMNP) applies a personalized approach to
treatment and development of novel, highly targeted therapeutics to improve the
lives of patients with inflammatory diseases and cancer. Immunes oncology
pipeline includes bispecific antibodies, nanotherapeutics, including
NanomAbs(r), and several mid-to-late stage small molecules including
Ceplene(r), Azixa(r) and Crolibulin(r). Ceplene(r) is approved in over 30
European countries and Israel.  Immunes lead product candidate for the
treatment of inflammatory disease, bertilimumab, is in phase II clinical
development for moderate-to-severe ulcerative colitis as well as for bullous
pemphigoid, an orphan autoimmune dermatological condition. Other indications
being considered for development include atopic dermatitis, Crohns disease,
severe asthma and NASH (an inflammatory liver disease). Immune recently
expanded its portfolio in immuno-dermatology with topical nano-formulated
cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immunes
non-core pipeline includes AmiKet(tm), a late clinical stage drug candidate for
the treatment of neuropathic pain. For more information, visit Immunes website
at www.immunepharmaceuticals.com http://www.immunepharmaceuticals.com/ , the
content of which is not a part of this press release. 

Forward-Looking Statements
This news release and any oral statements made with respect to the information
contained in this news release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. You are urged
to consider statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed," "goal" or the
negative of those words or other comparable words to be uncertain and
forward-looking. Such forward-looking statements include statements that
express plans, anticipation, intent, contingency, goals, targets, future
development and are otherwise not statements of historical fact. These
statements are based on our current expectations and are subject to risks and
uncertainties that could cause actual results or developments to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause actual
results or developments to differ materially include, but not limited to: the
risks associated with the adequacy of our existing cash resources and our
ability to continue as a going concern; the risks associated with our ability
to continue to meet our obligations under our existing debt agreements; the
risk that clinical trials for bertilimumab or AmiKet will not be successful;
the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs
program will not receive regulatory approval or achieve significant commercial
success; the risk that we will not be able to find a partner to help conduct
the Phase III trials for AmiKet on attractive terms, on a timely basis or at
all; the risk that our other product candidates that appeared promising in
early research and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later-stage clinical trials; the risk that we will not obtain
approval to market any of our product candidates; the risks associated with
dependence upon key personnel; the risks associated with reliance on
collaborative partners and others for further clinical trials, development,
manufacturing and commercialization of our product candidates; the cost, delays
and uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating
losses since our inception; the highly competitive nature of our business;
risks associated with litigation; and risks associated with our ability to
protect our intellectual property. These factors and other material risks are
more fully discussed in our periodic reports, including our reports on Forms
8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange
Commission. You are urged to carefully review and consider the disclosures
found in our filings, which are available at www.sec.gov http://www.sec.gov/ 
or at www.immunepharmaceuticals.com http://www.immunepharmaceuticals.com/ . You
are cautioned not to place undue reliance on any forward-looking statements,
any of which could turn out to be wrong due to inaccurate assumptions, unknown
risks or uncertainties or other risk factors. We expressly disclaim any
obligation to publicly update any forward looking statements contained herein,
whether as a result of new information, future events or otherwise, except as
required by law. 

SOURCE Immune Pharmaceuticals, Inc.